"Dr. Jon Giles didn't expect to have any problems drumming up interest in his clinical trial testing if hydroxychloroquine can help prevent COVID-19.
"We were getting calls all the time from people who were interested," says
Giles, an epidemiologist and rheumatologist at Columbia University.
For his study, Giles planned to give a short course of the medication to people who were "household contacts" of COVID-19 patients. Like many of the ongoing trials, it would be randomized with a control group.
By the end of April, Giles was ready to start enrolling people. But his team ran into a problem when they started calling potential participants.
"Pretty much everybody said, Well that's the drug that's dangerous to your heart, or, I talked to my friends and they said don't take it, or that I saw on TV it's dangerous," says Giles.
Just a month earlier, he says demand for the drug was soaring. Some patients with auto-immune conditions
couldn't even get their prescriptions filled, after President Trump spoke enthusiastically about the drug.
In April, the FDA issued a
warning about using the drug for COVID-19 patients without strict medical supervision in a hospital or as part of a clinical trial. The agency had received reports of serious heart-related adverse events and death in patients with COVID-19 receiving hydroxychloroquine and chloroquine.
But the back and forth headlines and the ongoing political wrangling seemed to make people wary of the medication, Giles says, even in the context of a carefully run clinical trial.
"It became almost impossible to get anyone interested," says Giles.
Giles says the committee overseeing his study added a new requirement: that study participants needed to have had an ECG within the last year.
As a rheumatologist, Giles knows the medication better than most doctors because he prescribes it to many of his patients.
"It's a very, very safe drug, it's been used for over 75 years," he says. "When I give someone hydroxychloroquine, I don't get an
ECG or do blood monitoring."
Giles was planning to enroll otherwise healthy people and screen out anyone who could be at risk of heart problems. But that new requirement, plus the negative press, made it too difficult to find study subjects.
He gave up on doing the study. He says it's a missed opportunity.
"It's not unreasonable to think that a short course of this drug might have some protective ability," he says." - NPR
Clap Clap Clap. Fear is your only God folks.